A Real-World Study Comparing Maintenance Chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (S-1) Versus Follow-Up Observation After Adjuvant Therapy for Resected Pancreatic Cancer with High Risk of Recurrence/Metastasis (MSPAC-1)

The goal of this real-world study is to learn if maintenance chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (S-1) can improve disease-free survival (DFS) compared to follow-up observation in patients with resected pancreatic cancer at high risk of recurrence or metastasis after adjuvant therapy. The main questions it aims to answer are:
* Does maintenance therapy with S-1 improve disease-free survival (DFS) compared to follow-up observation after standard treatment for resected high-risk pancreatic cancer?
* Does S-1 maintenance therapy improve overall survival (OS), distant disease-free survival (DDFS), and local recurrence-free survival (LRFS) compared to observation?
* What are the safety and tolerability profiles of S-1 maintenance therapy compared to observation? Researchers will compare two groups: the S-1 maintenance therapy group and the observation-only group, to see if S-1 improves survival outcomes and safety.
Participants will:
* Receive maintenance chemotherapy with S-1 based on body surface area dosing or be assigned to the observation group without drug intervention.
* Undergo imaging evaluations every 12 weeks to monitor for disease recurrence or metastasis.
* Report side effects and any adverse events during the study.

Start Date01 Apr 2025

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

NCT06789679

/ RecruitingPhase 2IIT

Randomized Phase II Clinical Study of Albumin-Bound Paclitaxel and Gemcitabine with or Without S-1 As First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

This study is a prospective, open-label, randomized controlled trial that enrolled previously untreated patients with locally advanced or metastatic pancreatic cancer. Participants were randomly assigned to receive either albumin-bound paclitaxel and gemcitabine, or albumin-bound paclitaxel, gemcitabine, and S-1 as first-line treatment. After patients who met the inclusion criteria signed an informed consent form, the study observed patients from the start of treatment until death, withdrawal of consent, loss to follow-up, or the end of the study. Eligible participants were randomly assigned in a 1:1 ratio to either the albumin-bound paclitaxel and gemcitabine treatment group (AG ) or the albumin-bound paclitaxel, gemcitabine, and S-1 treatment group (GAS). A total of 128 patients were planned for inclusion in the study, with 64 in each treatment group. Baseline data related to demographics, disease, treatment, adverse events, and tumor status were collected by the treating physician during the first visit and follow-up visits. Follow-up visits were conducted according to a fixed schedule, with survival assessed every three months through phone calls, WeChat, or by contacting other physicians. The final visit recorded patient death, withdrawal of consent, loss to follow-up, or the conclusion of the study.

Start Date15 Jan 2025

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

NCT06766578

/ Not yet recruitingPhase 2IIT

Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma(STAR-02)

To evaluate the initial efficacy and safety of neoadjuvant low-dose interval radiotherapy combined with tirelizumab and SOX chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma.

Start Date31 Dec 2024

Sponsor / Collaborator

Shandong Provincial Hospital

100 Clinical Results associated with Tegafur/Gimeracil/Oteracil Potassium

100 Translational Medicine associated with Tegafur/Gimeracil/Oteracil Potassium

100 Patents (Medical) associated with Tegafur/Gimeracil/Oteracil Potassium

6,426

Literatures (Medical) associated with Tegafur/Gimeracil/Oteracil Potassium

01 Jul 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Functional ionic liquid anchored TS-1 molecular sieve with multiple adsorption sites for efficient capture and separation of CO2 in flue gas systems

Author: Yuan, Maojie ; Liu, Yanduo ; Tang, Xuqi ; Guo, Xin ; Hu, Yufeng ; An, Yongqi ; Meng, Zitao ; Jiao, Jianhao ; Wang, Bingcan ; Qin, Yucai ; Li, Qiang ; Liu, Qinghua

Solid adsorption using porous mol. sieves are promising technol. to capture CO₂ from the air and industrial gases.However, the adsorption capacity and stability for most mol. sieves in complex gas systems are undesirable.The presence of alk. substances can improve the absorption capacity of materials by altering the surface properties and enhancing the interaction with CO₂.To improve the adsorption performance, we introduced amine functionalized ionic liquids (ILs) 1-aminopropyl-3-methylimidazolium bromide (APMImBr, with one amine group) and Bis-(3-aminopropyl-1-imidazole) ethylidene dibromide (BAPImEDB, with two amine group) on the surface of TS-1 mol. sieve.Under optimal exptl. conditions, APMImBr and BAPImEDB modified TS-1 mol. sieves have high adsorption capacity (increased by 148.5% and 218%, resp.) and universal adaptability and renewability.According to CO₂-TPD, XPS spectrum and quantum chem. calculations, the role of amine-based ILs can significantly enhance the weak and medium-strength basic sites, forming a multi-point alk. effect and enhancing the adsorption capacity through weak interactions (van der waals and hydrogen bonding) with CO₂.Overall, the research on multi amine functionalized ionic liquid composite solid adsorbents based on porous mol. sieves for carbon dioxide capture and recovery provides valuable insights for achieving sustainable development goals.

01 Jun 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Hydroxyl and amino co-modified imidazole based ionic liquid functionalized TS-1 molecular sieve for efficient CO2 capture

Author: Liu, Yanduo ; Dai, Lina ; Dong, Xianglan ; Zhang, Enqi ; Yin, Yue

Herein, an integrative solid adsorbent of [AHOPMIm]Cl with hydroxyl and amino groups functional sites modified TS-1 mol. sieve is designed and fabricated for efficient CO2 adsorption.The optimal [AHOPMIm]Cl/TS-1 exhibits 73% enhancement in CO2 adsorption capacity compared with the TS-1 mol. sieve, even outperforming other state of the art adsorbent systems.The greatly improved CO2 adsorption capacity is mainly attributed to the strong adsorption of amino groups on the ionic liquids surface, which can form low-temperature stable amino ester species.Moreover, it is preserved that the hydroxyl groups on the surface of ionic liquids can form stable hydrogen bonds with oxygen atoms in CO2, and coordinate with amino groups to capture CO2 from different directions based on in situ DRIFTS and DFT.The porous TS-1 mol. sieve provides a structural basis for the uniform dispersion, effective support, and enhanced CO2 adsorption capacity of ionic liquidsA new design concept for constructing ionic liquid-based composite adsorbent with dual functional sites using TS-1 mol. sieve as a carrier is provided, and the avenues for efficient CO2 adsorption are paved.

01 Apr 2025·SURGERY

Neoadjuvant gemcitabine and S-1 in pancreatic ductal adenocarcinoma: Effects on nutritional status and pancreaticoduodenectomy outcomes

Article

Author: Ban, Daisuke ; Esaki, Minoru ; Miyata, Akinori ; Mizui, Takahiro ; Nara, Satoshi ; Takamoto, Takeshi

BACKGROUND:

With the advent of improved chemotherapy options, neoadjuvant chemotherapy has gained acceptance as a multidisciplinary treatment approach for localized pancreatic ductal adenocarcinoma. This study aimed to clarify whether neoadjuvant chemotherapy with gemcitabine and S-1 influences preoperative nutritional status and postoperative outcomes, particularly in patients undergoing highly invasive pancreatic resection.

METHODS:

Patients with resectable pancreatic ductal adenocarcinoma who underwent pancreaticoduodenectomy as upfront surgery or after neoadjuvant chemotherapy with gemcitabine and S-1 between January 2015 and December 2022 were assessed. In addition to perioperative surgical outcomes, preoperative nutritional status was evaluated using serum albumin, controlling nutritional status, and prognostic nutritional index.

RESULTS:

A total of 158 patients who underwent upfront pancreaticoduodenectomy and 119 who received neoadjuvant chemotherapy with gemcitabine and S-1 before pancreaticoduodenectomy were evaluated. Preoperative nutritional assessments (serum albumin, controlling nutritional status score, and prognostic nutritional index) showed no significant differences between groups, either at the initial consultation or immediately before surgery. No significant differences were observed in postoperative outcomes, including blood loss, operation time, and morbidity. The neoadjuvant chemotherapy with gemcitabine and S-1 group had a significantly greater rate of negative tumor margins (R0 resection rate 86% vs 74%, P = .018), and improved overall survival (hazard ratio, 0.41; 95% confidence interval, 0.25-0.67, P < .001) compared with the upfront pancreaticoduodenectomy group.

CONCLUSIONS:

Neoadjuvant chemotherapy with gemcitabine and S-1 does not adversely impact preoperative nutritional status and enhances the effectiveness of pancreaticoduodenectomy for resectable pancreatic ductal adenocarcinoma, leading to improved pathologically curative resection rates and overall survival.

News (Medical) associated with Tegafur/Gimeracil/Oteracil Potassium

04 Dec 2024

·www.businesswire.com

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

TOKUSHIMA, Japan--( BUSINESS WIRE )--We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. We had presented these results at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation. DFP-17729 is a novel approach to neutralize the acidic cancer microenvironment, and several patents on related inventions have been granted in major countries around the world, and its potential of efficacy has been published in peer-reviewed journals. We will first identify DFP-17729 as a treatment for refractory pancreatic cancer, for which effective treatment is not yet available, and then seek to expand the indication to other types of cancer through partnership with major global pharmaceutical companies. Please take notice of our own innovative approach for miserable cancer patients and contact us.

Clinical ResultPhase 1IND

05 Jun 2024

·www.prnewswire.com

RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment

YANTAI, China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024, sharing major research results including its proprietary antibody drug conjugates (ADCs) Disitamab Vedotin (RC48) and RC88. RemeGen's innovative drugs featured in one Clinical Science Symposium, five Poster presentations, and ten online Abstracts at ASCO 2024, covering multiple cancer types including gastric and bladder cancer, and gynecological tumors in studies that included both monotherapy and combination therapies. Dr. Jianmin Fang, CEO of RemeGen, commented, "It is always such an honor to present our latest research findings on an internationally renowned stage such as ASCO Annual Meeting 2024. This not only demonstrates RemeGen's leading position in the field of antibody-drug conjugates in China but also proves our commitment to continuing our research efforts to provide effective treatment options for patients worldwide." Clinical Science Symposium First author Professor Song Li from Qilu Hospital of Shandong University gave an oral presentation at a Clinical Science Symposium at ASCO 2024 based on a randomized, controlled (RCT) multicenter, single-arm, Phase II trial investigating the efficacy of RemeGen's disitamab vedotin (RC48) combined with toripalimab and the oral fluoropyrimidine S-1 in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma. Poster Sessions First author Professor Sheng Xinan from Peking University Cancer Hospital presented RemeGen's poster session (Poster #263) of a Phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) focusing on the preliminary efficacy and safety results of RC48-C017. The standard of care for MIBC is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy plus pelvic lymph node dissection (RC + PLND). Disitamab vedotin monotherapy, or combined therapy with toripalimab, showed promising anti-tumor activity in metastatic urothelial carcinoma. This Phase II trial aimed to evaluate the safety and efficacy of disitamab vedotin plus toripalimab as perioperative therapy in MIBC patients and the interim results presented at ASCO showed promising efficacy results with a manageable safety profile in operable MIBC patients. These results support further investigation for disitamab vedotin plus toripalimab in this population. Other poster presentations included a Phase II multi-center study in poster session (poster #311a) on adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 expression; and a prospective, single-arm, single-center clinical study in poster session (poster #513a) on disitamab vedotin combined with toripalimab in patients with advanced penile cancer who have progressed on treatment or are intolerant to cisplatin chemotherapy. Online Abstract Publications Ten other online abstracts accepted by ASCO reflected results of RemeGen's RC48 and RC88 in bladder, breast, and GI cancers, demonstrating the Company's prolific innovation in global cancer treatment. About ASCO The ASCO 2024 meeting is the premier event for strategies to improve quality care in oncology. It provides superb panels featuring experts who are leading and implementing innovative programs focused on value. ASCO's diverse network of nearly 42,350 oncology professionals recognizes ASCO's dedication to providing the highest-quality resources in education, policy, the pioneering of clinical research, and above all, advancing the care for patients with cancer. About RemeGen Co. Ltd. Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases. For more details, please visit: About Disitamab Vedotin (RC48) Disitamab Vedotin (RC48) is an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid cancers with significant unmet medical needs and is the first domestically developed ADC to receive marketing approval in China. The company is implementing a differentiated development and commercial strategy for disitamab vedotin, including (i) gastric cancer (GC), (ii) urothelial carcinoma (UC), (iii) breast cancer (BC), and (iv) other HER2-expressing cancers. SOURCE RemeGen Co., Ltd

Clinical ResultASCOADCPhase 2

02 Mar 2024

·www.globenewswire.com

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,150,000 shares of common stock of the Company originally issued in October 2023, having an exercise price of $2.82 per share and eighteen months term. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-275397). The gross proceeds to the Company from the exercise of the warrants are expected to be $3,530,500, prior to deducting placement agent fees and estimated offering expenses. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. In consideration for the immediate exercise of the warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to 2,300,000 shares of common stock. The new warrants will have an exercise price of $2.82 per share, will be immediately exercisable upon issuance and will have a term of eighteen months from the issuance date. The offering is expected to close on or about March 6, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds for general corporate purposes, including general and administrative expenses, working capital and to support regulatory and clinical activities related to AD04, its lead investigational drug product for the treatment of Alcohol Use Disorder (AUD). The new warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares of common stock underlying the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com. Forward-Looking Statements This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include without limitation, statements regarding the closing of the private placement, the satisfaction of the closing conditions of the private placement, and the use of net proceeds from the private placement as well as the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, market and other conditions, our ability to pursue our regulatory strategy, our ability to maintain our Nasdaq listing, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to retain our key employees or maintain our Nasdaq listing, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2022, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Investor Contact Crescendo Communications, LLCDavid Waldman / Alexandra SchiltTel: 212-671-1020Email: adil@crescendo-ir.com

Phase 3Clinical Result

100 Deals associated with Tegafur/Gimeracil/Oteracil Potassium

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tegafur/Gimeracil/Oteracil Potassium	L01BC53	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hormone receptor positive HER2 positive breast cancer	JP	Taiho Pharmaceutical Co., Ltd.	24 Nov 2022
Hormone receptor positive HER2 negative breast cancer	JP	OKAYAMA TAIHO Pharmaceutical Co., Ltd.	15 Feb 2017
Advanced gastric carcinoma	EU	Nordic Group BV	14 Mar 2011
Advanced gastric carcinoma	IS	Nordic Group BV	14 Mar 2011
Advanced gastric carcinoma	LI	Nordic Group BV	14 Mar 2011
Advanced gastric carcinoma	NO	Nordic Group BV	14 Mar 2011
Metastatic Colorectal Carcinoma	EU	Nordic Group BV	14 Mar 2011
Metastatic Colorectal Carcinoma	IS	Nordic Group BV	14 Mar 2011
Metastatic Colorectal Carcinoma	LI	Nordic Group BV	14 Mar 2011
Metastatic Colorectal Carcinoma	NO	Nordic Group BV	14 Mar 2011
Stomach Cancer	CN	Shandong New Time Pharmaceutical Co. Ltd.	19 Dec 2008
Biliary Tract Neoplasms	JP	Taiho Pharmaceutical Co., Ltd.	23 Aug 2007
Pancreatic Cancer	JP	Taiho Pharmaceutical Co., Ltd.	10 Aug 2006
Breast Cancer	JP	Taiho Pharmaceutical Co., Ltd.	14 Nov 2005
Non-Small Cell Lung Cancer	JP	Taiho Pharmaceutical Co., Ltd.	14 Dec 2004
Colorectal Cancer	JP	Taiho Pharmaceutical Co., Ltd.	17 Dec 2003
Head and Neck Neoplasms	JP	Taiho Pharmaceutical Co., Ltd.	04 Apr 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastrooesophageal junction cancer	Phase 3	US	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	AR	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	BE	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	BR	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	BG	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	HR	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	EE	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	DE	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	HU	Taiho Oncology, Inc.	14 Apr 2011
Gastrooesophageal junction cancer	Phase 3	IL	Taiho Oncology, Inc.	14 Apr 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04999332 (ASCO_GI2025)	Phase 2	Locally Advanced Gastroesophageal Junction Adenocarcinoma	-	Leucovorin, Oxaliplatin, Docetaxel, S-1 (LOTS)	dvrkuhgezr(vydtzhlgys) = uxoibjpcuy icbsbpfzeo (ieaycxyqah ) View more	Positive	23 Jan 2025
				5-fluorouracil, Oxaliplatin, Docetaxel, Leucovorin (FLOT)	dvrkuhgezr(vydtzhlgys) = szbistymar icbsbpfzeo (ieaycxyqah ) View more
ASCO_GI2025	Not Applicable	Pancreatic Cancer Adjuvant	129	S-1 (Induction within 2 weeks after surgery)	zifgzcilff(akynsepjtj) = yvejaluwca tgzannqjup (jgibuceysw ) View more	Positive	23 Jan 2025
				S-1 (Induction within 3-6 weeks after surgery)	zifgzcilff(akynsepjtj) = zcwshjyvur tgzannqjup (jgibuceysw ) View more
NCT04999332 (ESMO_ASIA2024) Manual	Phase 2	Locally Advanced Gastroesophageal Junction Adenocarcinoma \| Locally Advanced Gastric Carcinoma	46	Leucovorin, Oxaliplatin, Docetaxel, S-1 (LOTS)	tveuupofsh(yqllxxjvah) = lpyblpebiy iartzzujja (pknantgxqd ) View more	Positive	07 Dec 2024
ESMO_ASIA2024	Not Applicable	Adjuvant	73	Completion group (S-1 chemotherapy for 1 year)	ymnpqilvof(kalnmnhibh) = ucciimnzmz shoujabryi (qhpnpuccgc ) View more	Negative	07 Dec 2024
				Non-completion group (did not complete S-1 chemotherapy)	gblgrdaafs(ztrdbumymi) = qcadzfrwsv nrfppkkdea (oxczaoxytv ) View more
NCT05026905 (TCOG T5221, ESMO2024) Manual	Phase 2	Pancreatic Cancer First line	50	GASL (Gemcitabine plus nab-paclitaxel and S-1/leucovorin	lvzljcjkft(ltxfllwsyl) = nxtxawlyej qwfxjwthld (tpjtvbgcdv ) View more	Positive	16 Sep 2024
				GAP (Gemcitabine plus nab-paclitaxel and oxaliplatin)	lvzljcjkft(ltxfllwsyl) = pgdxmizkbp qwfxjwthld (tpjtvbgcdv ) View more
NCT03636308 (Pubmed) Manual	Phase 2	Pancreatic Cancer First line	62	nab-paclitaxel plus S-1 (AS)	cqthudlask(ttlhsvekep) = gfzqplukru dnahvcdyez (vbwvhjmwre ) View more	Positive	11 Jul 2024
				nab-paclitaxel plus gemcitabine (AG)	cqthudlask(ttlhsvekep) = xcykadjtmg dnahvcdyez (vbwvhjmwre ) View more
NCT03162510 (TCOG T1216, Pubmed) Manual	Phase 1	Gastrointestinal Neoplasms	-	nab-paclitaxeloxaliplatinS-1	kgyzsotlel(wqjgzgqfvc) = vburatugmu ivckmukoof (gwycxguuux ) View more	Positive	21 Jun 2024
JPRN-UMIN000026858 (GABARNANCE, ASCO2024) Manual	Phase 2/3	Pancreatic Cancer Neoadjuvant	112	Gemcitabine+nab-paclitaxel	mgnlznevqb(ckzzlfxhmb) = ahriraqimh cmxizincgh (odiywlbfpn ) View more	Positive	02 Jun 2024
				Concurrent chemoradiotherapy+S-1	mgnlznevqb(ckzzlfxhmb) = rcqkhptlyi cmxizincgh (odiywlbfpn ) View more
JPRN-UMIN000011688 (JCOG1202/ASCOT, ASCO2024) Manual	Phase 3	Biliary Tract Neoplasms Adjuvant	440	observation or S-1S-1	exyikvznhc(zswfnvzxha) = ywquuaswkj uiwpcyctex (szbgmtyhhr ) View more	Positive	24 May 2024
				Adjuvant S-1	rtjyzdhokd(nnwoymzamu) = xoqiilpyga awywvjfsdq (qjtkujunvv ) View more
NCT03814759 (ASCO2024)	Phase 2	Advanced gastric carcinoma Neoadjuvant	49	Neoadjuvant S-1/Cisplatin-based chemoradiotherapy	lknrpwycrp(eufavwordq) = qtdgermhwr xofeymopbe (qignsfdsjl ) View more	Positive	24 May 2024
				S-1 (Surgery alone)	lknrpwycrp(eufavwordq) = ogiphbfeam xofeymopbe (qignsfdsjl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis